- Report
- March 2024
- 189 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- October 2023
- 135 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- April 2024
- 359 Pages
Global
From €5260EUR$5,450USD£4,512GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 140 Pages
Global
From €3763EUR$3,899USD£3,228GBP
- Report
- January 2024
- 150 Pages
Global
From €4681EUR$4,850USD£4,016GBP
- Report
- February 2024
- 110 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Drug Pipelines
- June 2018
- 31 Pages
Global
From €3378EUR$3,500USD£2,898GBP
- Drug Pipelines
- October 2018
- 29 Pages
Global
From €3378EUR$3,500USD£2,898GBP
- Report
- February 2024
- 189 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Book
- September 2019
- 272 Pages
Arrestins are a family of proteins that play a key role in the regulation of G-protein coupled receptors (GPCRs). They are involved in the termination of GPCR signaling, and are also involved in the regulation of other cellular processes such as cell migration, cell adhesion, and cell proliferation. Arrestins are of particular interest in drug discovery, as they are involved in the regulation of many disease-related pathways. Arrestins have been implicated in a variety of diseases, including cancer, diabetes, and cardiovascular disease.
The arrestin market is a rapidly growing field, with a number of companies developing novel drugs targeting arrestins. Companies such as AbbVie, AstraZeneca, and Novartis are actively researching and developing drugs targeting arrestins. Other companies such as Merck, Pfizer, and Sanofi are also investing in the arrestin market, with a focus on developing new treatments for a variety of diseases. Show Less Read more